MedPath

Probiotics for Birch Pollen Allergy

Phase 1
Completed
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Biological: Lactobacillus acidophilus and Bifidobacterium lactis
Biological: Placebo
Registration Number
NCT00746226
Lead Sponsor
Danisco
Brief Summary

Birch pollen allergy is one of the most common forms of respiratory allergy in the Nordic countries. Treatment consists of antihistamine use. Specific probiotic strains have been observed to modulate the immune system. Since the body has a common mucosal immune system; it was hypothesised that consumption of probiotics may affect also the respiratory mucosal immune response and hence affect respiratory allergy.

Earlier studies with probiotics had been unable to show improvements in adults with pollen allergy. It was therefore hypothesised that children, who's immune system is not yet fully developed, might be better targets.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
47
Inclusion Criteria

Physician verified birch pollen allergy

Exclusion Criteria

Diagnosed asthma Habitual use of probiotics and/or prebiotics

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ALactobacillus acidophilus and Bifidobacterium lactisNumbers 509-513, 700-709 and 900-909 Probiotic combination of L. acidophilus and B. lactis
BPlaceboNumbers 612-624 and 800-811 Microcrystalline cellulose
Primary Outcome Measures
NameTimeMethod
Birch pollen allergy symptomsMarch/April and June
Nasal EosinophiliaApril/May and June
Secondary Outcome Measures
NameTimeMethod
Change in microbiota compositionApril/May and June
Cytokine profile from serumApril/May and June
Faecal recovery of administered probioticsApril/May and June

Trial Locations

Locations (1)

Turku University Central Hospital

🇫🇮

Turku, Finland

© Copyright 2025. All Rights Reserved by MedPath